BR112021018295A2 - Composições e métodos para tratamento de câncer - Google Patents
Composições e métodos para tratamento de câncerInfo
- Publication number
- BR112021018295A2 BR112021018295A2 BR112021018295A BR112021018295A BR112021018295A2 BR 112021018295 A2 BR112021018295 A2 BR 112021018295A2 BR 112021018295 A BR112021018295 A BR 112021018295A BR 112021018295 A BR112021018295 A BR 112021018295A BR 112021018295 A2 BR112021018295 A2 BR 112021018295A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- egfr
- treating cancer
- present disclosure
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- 208000005017 glioblastoma Diseases 0.000 abstract 2
- 230000004153 glucose metabolism Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
composições e métodos para tratamento de câncer. a presente divulgação refere-se a compostos que são capazes de penetrar na barreira hematoencefálica para modular a atividade da tirosina quinase egfr. a divulgação refere-se ainda a métodos de tratamento de glioblastoma e outros cânceres mediados por egfr. a divulgação refere-se ainda a métodos de tratamento de glioblastoma e outros cânceres mediados por egfr que foram determinados como tendo o metabolismo da glicose alterado na presença de inibidores. a presente divulgação também fornece métodos de administração a um sujeito de um inibidor do metabolismo da glicose e um estabilizador citoplasmático de p53.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819322P | 2019-03-15 | 2019-03-15 | |
| US201962904241P | 2019-09-23 | 2019-09-23 | |
| PCT/US2020/022743 WO2020190765A2 (en) | 2019-03-15 | 2020-03-13 | Compositions and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018295A2 true BR112021018295A2 (pt) | 2021-11-23 |
Family
ID=72521289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018295A BR112021018295A2 (pt) | 2019-03-15 | 2020-03-13 | Composições e métodos para tratamento de câncer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11377451B2 (pt) |
| EP (1) | EP3938354A4 (pt) |
| JP (1) | JP7474269B2 (pt) |
| KR (1) | KR20210151820A (pt) |
| CN (2) | CN115215808A (pt) |
| AU (1) | AU2020241703A1 (pt) |
| BR (1) | BR112021018295A2 (pt) |
| CA (1) | CA3133688A1 (pt) |
| CL (1) | CL2021002409A1 (pt) |
| CO (1) | CO2021013496A2 (pt) |
| CR (1) | CR20210498A (pt) |
| IL (1) | IL286350A (pt) |
| MX (1) | MX2021011272A (pt) |
| SG (1) | SG11202109662YA (pt) |
| WO (1) | WO2020190765A2 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020536855A (ja) * | 2017-09-26 | 2020-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療するための組成物及び方法 |
| BR112021018295A2 (pt) | 2019-03-15 | 2021-11-23 | Univ California | Composições e métodos para tratamento de câncer |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061201A1 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022155311A1 (en) * | 2021-01-14 | 2022-07-21 | The Regents Of The University Of California | Methods and systems for analysis of drug target engagement and treatment of cancer |
| EP4337328A1 (en) * | 2021-05-12 | 2024-03-20 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
| CN113307799B (zh) * | 2021-05-21 | 2022-07-19 | 大连医科大学 | 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用 |
| AU2022350669A1 (en) * | 2021-09-23 | 2024-04-04 | Fritz Blatter | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) * | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
| WO2024081447A1 (en) * | 2022-10-14 | 2024-04-18 | The Regents Of The University Of California | Egfr inhibitors for treating lung cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법 |
| CN1854130B (zh) | 2005-04-15 | 2011-04-20 | 中国医学科学院药物研究所 | 喹唑啉衍生物、及其制法和药物组合物与用途 |
| WO2008046242A1 (fr) | 2006-10-16 | 2008-04-24 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations |
| ES2535176T3 (es) | 2009-09-28 | 2015-05-06 | Qilu Pharmaceutical Co., Ltd | Derivados de 4-(anilino sustituido)quinazolina como inhibidores de la tirosina quinasa |
| ITPD20110091A1 (it) | 2011-03-24 | 2012-09-25 | Univ Padova | Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico. |
| US10206924B2 (en) * | 2014-12-15 | 2019-02-19 | The Regents Of The University Of Michigan | Small molecule inhibitors of EGFR and PI3K |
| CN105017163A (zh) | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| US10473255B2 (en) | 2015-12-29 | 2019-11-12 | Ge-Hitachi Nuclear Energy Americas Llc | Reactor pressure vessel including pipe restraint device, and/or a pipe restraint device |
| WO2017117680A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
| CN106432202B (zh) | 2016-09-22 | 2019-04-02 | 郑州大学第一附属医院 | 喹唑啉类衍生物及其应用 |
| JP2020536855A (ja) | 2017-09-26 | 2020-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療するための組成物及び方法 |
| BR112021018295A2 (pt) | 2019-03-15 | 2021-11-23 | Univ California | Composições e métodos para tratamento de câncer |
| US20240058340A1 (en) | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2022061299A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Non-invasive functional companion assays for oncogene targeted therapy for brain cancer |
| WO2022061201A1 (en) | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| AU2022350669A1 (en) | 2021-09-23 | 2024-04-04 | Fritz Blatter | Egfr inhibitor polymorph forms |
| WO2023244639A1 (en) | 2022-06-14 | 2023-12-21 | The Regents Of The University Of California | Methods of predicting cns cancer response to treatment with egfr inhibitors |
-
2020
- 2020-03-13 BR BR112021018295A patent/BR112021018295A2/pt unknown
- 2020-03-13 EP EP20773177.9A patent/EP3938354A4/en active Pending
- 2020-03-13 CA CA3133688A patent/CA3133688A1/en active Pending
- 2020-03-13 CR CR20210498A patent/CR20210498A/es unknown
- 2020-03-13 CN CN202210268803.XA patent/CN115215808A/zh active Pending
- 2020-03-13 KR KR1020217032873A patent/KR20210151820A/ko unknown
- 2020-03-13 WO PCT/US2020/022743 patent/WO2020190765A2/en active Application Filing
- 2020-03-13 MX MX2021011272A patent/MX2021011272A/es unknown
- 2020-03-13 SG SG11202109662Y patent/SG11202109662YA/en unknown
- 2020-03-13 JP JP2021555445A patent/JP7474269B2/ja active Active
- 2020-03-13 CN CN202080034742.XA patent/CN113811528A/zh active Pending
- 2020-03-13 AU AU2020241703A patent/AU2020241703A1/en active Pending
-
2021
- 2021-09-13 IL IL286350A patent/IL286350A/en unknown
- 2021-09-14 US US17/475,144 patent/US11377451B2/en active Active
- 2021-09-15 CL CL2021002409A patent/CL2021002409A1/es unknown
- 2021-10-11 CO CONC2021/0013496A patent/CO2021013496A2/es unknown
-
2022
- 2022-06-29 US US17/853,573 patent/US20230115366A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002409A1 (es) | 2022-06-17 |
| US20230115366A1 (en) | 2023-04-13 |
| EP3938354A4 (en) | 2022-12-28 |
| JP7474269B2 (ja) | 2024-04-24 |
| CN115215808A (zh) | 2022-10-21 |
| CN113811528A (zh) | 2021-12-17 |
| CA3133688A1 (en) | 2020-09-24 |
| SG11202109662YA (en) | 2021-10-28 |
| WO2020190765A2 (en) | 2020-09-24 |
| JP2022526266A (ja) | 2022-05-24 |
| WO2020190765A3 (en) | 2020-11-26 |
| CO2021013496A2 (es) | 2022-01-17 |
| KR20210151820A (ko) | 2021-12-14 |
| US20220064177A1 (en) | 2022-03-03 |
| CR20210498A (es) | 2022-01-11 |
| US11377451B2 (en) | 2022-07-05 |
| IL286350A (en) | 2021-10-31 |
| MX2021011272A (es) | 2021-10-01 |
| AU2020241703A1 (en) | 2021-10-14 |
| EP3938354A2 (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021018295A2 (pt) | Composições e métodos para tratamento de câncer | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| CL2020002945A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t | |
| BRPI0511139B8 (pt) | compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos | |
| BRPI0511760A (pt) | tratamento com gemcitabina e um inibidor de egfr | |
| AR054566A1 (es) | Tratamientoombinado de los tumores que expresan el her | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
| GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| CO6331446A2 (es) | Composiciones farmaceúticas que comprenden la combinación de un agente antimitotico y un compuesto inhibidor de aurora quinasa, utiles en el tratamiento anticancerígeno | |
| BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
| MX2021014455A (es) | Inhibidores de proteina cinasas dependientes de adn. | |
| GT201000172A (es) | Inhibidores de cinesina como productos terapéuticos para el cáncer | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| BRPI0517075A (pt) | uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer | |
| BR112021017616A2 (pt) | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| BR112015029550A2 (pt) | Anticorpo anti-vegf e composição farmacêutica para prevenção, diagnóstico ou tratamento de câncer ou doença relacionada à angiogênese contendo o mesmo | |
| ECSP22043592A (es) | Inhibidores de egfr alost?ricos y m?todos de uso de los mismos | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| BR112022009631A2 (pt) | Combinações de inibidores de dgk e antagonistas do ponto de checagem | |
| BR112022014968A2 (pt) | Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade | |
| CL2022002410A1 (es) | Terapia combinada de inhibidores axl/mer y pd-1/pd-l1. |